Skip to main content
. 2023 Jan 11;16:71–77. doi: 10.2147/CCID.S391893

Figure 3.

Figure 3

Clinical signs and symptom scores at baseline, Day 15 and Day 30. M89Pf significantly (p<0.0001) reduced clinical signs and symptoms as early as Day 15.